Prostate Cancer

"It will only be when the indications for focal therapy are expanded to higher-grade and larger tumors that we will begin to learn about the true efficacy of this approach," writes Badar M. Mian, MD.

Treatment with rucaparib reduced risk of imaging-based progression or death by half in men with BRCA-altered metastatic castration-resistant prostate cancer.

The combination use of niraparib plus abiraterone and prednisone continued to improve outcomes in patients with metastatic, castration-resistant prostate cancer and HRR gene alterations.

Expert perspectives on strategies to optimize communication, both between healthcare professionals and with patients who present with prostate cancer.

Cardiologist Anees A. Daud, MD, breaks down the typical patient with prostate cancer seen at his practice.

Urologist David Morris, MD, FACS, defines the typical patient with prostate cancer treated at his practice.

Oncologist Joelle Hamilton, MD, shares her perspective on the typical patient with prostate cancer seen at her institution.

Centering focus on a patient case of cardiovascular risk and prostate cancer, experts share their perspective on management strategies.

Comprehensive insight regarding strategies to mitigate cardiovascular risk in patients on therapy for prostate cancer.

Shared insight on a timeline of clinical studies contextualizing cardiovascular disease in the setting of prostate cancer management.

Expert perspectives on the risk of cardiovascular disease as it exists in the context of androgen deprivation therapy (ADT) and prostate cancer.

"We found that if the patient has normal IsoPSA, he has only 1% of risk of developing clinically significant prostate cancer in a median follow-up time of 18 months," says Nour Abdallah, MD.

The GPS test uses a 17-gene signature to predict disease aggressiveness and help guide treatment decisions for patients with localized prostate cancer.

"The reason that we really focus on prostate cancer is because it's amenable to early screening. Early detection is key in cure," says Janet Kukreja, MD, MPH, FACS.

IsoPSA is included in the National Comprehensive Cancer Network Prostate Cancer guidelines for early detection of the disease.

Barrigel is a hyaluronic acid rectal spacer indicated for patients with T1 to T3b prostate cancer disease.

Closing out his review of imaging modalities in the setting of prostate cancer, Brian Helfand, MD, PhD, looks toward future evolutions in detection and treatment.

Expert perspective on next steps for physicians and patients following a negative imaging result when recurrent prostate cancer is suspected.

Moving on to the second patient case of prostate cancer, Brian Helfand, MD, PhD, shares context for negative imaging results in this setting.

A brief discussion on how selection of imaging should be approached for patients receiving androgen deprivation therapy (ADT) for prostate cancer.

Following his review of available imaging modalities, Brian Helfand, MD, PhD, considers which scans are most appropriate based on patient and disease factors.

A comprehensive review of imaging modalities available to patients with prostate cancer who are suspected of recurrence.

Specialist Brian Helfand, MD, PhD, reviews the case of a 65-year-old man with prostate cancer and shares insight on strategies to monitor for recurrence.

Patients in the trial received switch maintenance with darolutamide following prior taxane chemotherapy and at least 1 androgen-receptor pathway inhibitor.

“It seems like podcasts really are a good way for people to learn about even a complex topic like this,” says Stacy Loeb, MD, MSc.

"The test is fast, minimally invasive, and cost-effective, and opens up a new suite of tools that will help us optimize treatment and quality of life for prostate cancer patients,” said Edwin Posadas, MD.

Study participants were randomly assigned to receive 6 months of HT plus local therapy or 6 months of HT alone.

“Where we really need to see change is talking about what the patient wants, what they're worried about, and what would work best for them,” says Angela Fagerlin, PhD.

The application for darolutamide in the European Union is supported by findings from the phase 3 ARASENS trial.

“If there is such a clear difference between what different physicians are recommending, that calls into the need for patients to be more involved in decisions,” says Angela Fagerlin, PhD.